Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer

References

• SmallEJSchellhammerPFHiganoCSPlacebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancerJ Clin Oncol200624193089309416809734
   PubMed Web of Science ®Google Scholar
• de BonoJSOudardSOzgurogluMTROPIC InvestigatorsPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialLancet201037697471147115420888992
   PubMed Web of Science ®Google Scholar
• de BonoJSLogothetisCJMolinaAAbiraterone and increased survival in metastatic prostate cancerN Engl J Med2011364211995200521612468
   PubMed Web of Science ®Google Scholar
• ScherHIFizaziKSaadFAFFIRM InvestigatorsIncreased survival with enzalutamide in prostate cancer after chemotherapyN Engl J Med2012367131187119722894553
   PubMed Web of Science ®Google Scholar
• ParkerCNilssonSHeinrichDALSYMPCA InvestigatorsAlpha emitter radium-223 and survival in metastatic prostate cancerN Engl J Med2013369321322323863050
   PubMed Web of Science ®Google Scholar
• RiceKHudakJPeayKComprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinicUrology20107651231123820579698
   PubMed Web of Science ®Google Scholar
• BorsòEBoniGGalliLRadium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancerFuture Oncol201411219
   Web of Science ®Google Scholar
• ConnellNMegaAECastilloJAssessment of the effectiveness of a prechemotherapy teaching session: a Brown University Oncology Group studyJ Clin Oncol201230Suppl 34 abstr 260
   Web of Science ®Google Scholar
• Xofigo (Radium Ra 223 Dichloride) Injection, for Intravenous Use [Package Insert]Wayne, NJBayer HealthCare Pharmaceuticals Inc2013
   Google Scholar
• Metastron (Strontium-89 Chloride Injection) [Prescribing Information]Arlington Heights, ILMedi-Physics Inc., Amersham Healthcare1998
   Google Scholar
• Quadramet (Samarium Sm 153 Lexidronam Injection) [Prescribing Information]Langhorne, PAEUSA Pharma2009
   Google Scholar
• Age-dependent doses to members of the public from intake of radionuclides: Part 2. Ingestion dose coefficients. A report of a Task Group of Committee 2 of the International Commission on Radiological ProtectionAnn ICRP1993233–41167
   Google Scholar
• BrulandOSNilssonSFisherDRLarsenRHHigh-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?Clin Cancer Res20061220 pt 26250s6257s17062709
   PubMed Web of Science ®Google Scholar
• RubiniGNicolettiARubiniDAsabellaANRadiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radiumCancer Biother Radiopharm201429111124180669
   PubMed Web of Science ®Google Scholar
• PorterATMcEwanAJPoweJEResults of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancerInt J Radiat Oncol Biol Phys19932558058138478230
   PubMed Web of Science ®Google Scholar
• OosterhofGORobertsJTde ReijkeTMStrontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary GroupEur Urol200344551952614572748
   PubMed Web of Science ®Google Scholar
• QuiltyPMKirkDBolgerJJA comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancerRadiother Oncol199431133407518932
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer – v2.20142014 Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines_nojava.aspAccessed October 1, 2014
   Google Scholar
• BaschELoblawDAOliverTKSystemic therapy in men with metastatic castration-resistant prostate cancer: American society of clinical oncology and cancer care Ontario clinical practice guidelineJ Clin Oncol201432303436344825199761
   PubMed Web of Science ®Google Scholar
• CooksonMSRothBJDahmPCastration-resistant prostate cancer:AUA GuidelineAmerican Urological Association2014 Available from: http://www.auanet.org/common/pdf/education/clinical-guidance/Castration-Resistant-Prostate-Cancer.pdfAccessed October 1, 2014
   Google Scholar
• HorwichAParkerCde ReijkeTKatajaVProstate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201324Suppl 6vi106vi11423813930
   PubMed Web of Science ®Google Scholar
• European Society for Medical Oncology (ESMO)Guidelines for the Treatment of Metastatic Castration-Resistant Prostate CancerEuropean Society for Medical Oncology2014 Available from: http://www.esmo.org/Guidelines-Practice/Pocket-Guidelines-Mobile-AppAccessed October 1, 2014
   Google Scholar
• SartorOColemanRNilssonSEffect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialLancet Oncol201415773874624836273
   PubMed Web of Science ®Google Scholar
• NilssonSLarsenRHFossåSDFirst clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastasesClin Cancer Res200511124451445915958630
   PubMed Web of Science ®Google Scholar
• NilssonSFranzénLParkerCBone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II studyLancet Oncol20078758759417544845
   PubMed Web of Science ®Google Scholar
• NilssonSStrangPAksnesAKA randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancerEur J Cancer201248567868622341993
   PubMed Web of Science ®Google Scholar
• O’SullivanJMSartorOParkerCExternal-beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trialAnn Oncol201425Suppl 4iv263
   Web of Science ®Google Scholar
• AntonarakisESLuCWangHAR-V7 and resistance to enzalutamide and abiraterone in prostate cancerN Engl J Med2014371111028103825184630
   PubMed Web of Science ®Google Scholar
• BadrisingSvan der NoortVvan OortIMClinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatmentCancer2014120796897524382803
   PubMed Web of Science ®Google Scholar
• NoonanKLNorthSBittingRLArmstrongAJEllardSLChiKNClinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamideAnn Oncol20132471802180723585511
   PubMed Web of Science ®Google Scholar
• SartorOGillessenSTreatment sequencing in metastatic castrate-resistant prostate cancerAsian J Androl201416342643124675654
   PubMed Web of Science ®Google Scholar
• CisloPSchererJREffects of radium-223 dichloride on risk for hospitalization and healthcare resource use in the phase 3 ALSYMPCA trialJ Clin Oncol201432Suppl 30 abstr 21
   Google Scholar
• GomellaLGLinJHoffman-CensitsJEnhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experienceJ Oncol Pract201066e5e1021358951
   PubMedGoogle Scholar
• SommersBDBeardCJD’AmicoAVKaplanIRichieJPZeckhauserRJPredictors of patient preferences and treatment choices for localized prostate cancerCancer200811382058206718704993
   PubMed Web of Science ®Google Scholar
• JangTLBekelmanJELiuYPhysician visits prior to treatment for clinically localized prostate cancerArch Intern Med2010170544045020212180
   PubMedGoogle Scholar
• MadsenLTCraigCKubanDA multidisciplinary prostate cancer clinic for newly diagnosed patients: developing the role of the advanced practice nurseClin J Oncol Nurs200913330530919502188
   PubMed Web of Science ®Google Scholar